Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18ClN5O |
| Molecular Weight | 355.821 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCCNC1=NC=CC(=C1)C2=NC(NC3=CC=CC(Cl)=C3)=NC=C2
InChI
InChIKey=IYNDTACKOAXKBJ-UHFFFAOYSA-N
InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23021994
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23021994
CGP60474 is a promising inhibitor of CDK1 with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Expanding the diversity of allosteric bcr-abl inhibitors. | 2010-10-14 |
|
| Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy. | 2005-06-24 |
|
| A genome-wide overexpression screen in yeast for small-molecule target identification. | 2005-01 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16IP6G5MLC
Created by
admin on Mon Mar 31 22:49:29 GMT 2025 , Edited by admin on Mon Mar 31 22:49:29 GMT 2025
|
PRIMARY | |||
|
164658-13-3
Created by
admin on Mon Mar 31 22:49:29 GMT 2025 , Edited by admin on Mon Mar 31 22:49:29 GMT 2025
|
PRIMARY | |||
|
DTXSID00167788
Created by
admin on Mon Mar 31 22:49:29 GMT 2025 , Edited by admin on Mon Mar 31 22:49:29 GMT 2025
|
PRIMARY | |||
|
644215
Created by
admin on Mon Mar 31 22:49:29 GMT 2025 , Edited by admin on Mon Mar 31 22:49:29 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
